What does it mean to participate in a clinical trial

The Institut de la Màcula runs a clinical trial program focused on researching new treatments for vision diseases. The Institute’s clinical trial program offers the opportunity to access the most innovative treatments, at no cost to the patient, and lasting between 1 and 2 years.

A clinical trial is the only way to access new drugs that are not yet available on the market. There are a large number of ocular diseases that currently have no cure, which is why research into new techniques and drugs is essential to confirm their effectiveness and pave the way to treat and cure these conditions.

Since its inception, the Institut de la Màcula has conducted several clinical trials aimed at investigating innovative treatments or new ways of applying existing ones, in order to cure diseases that still have no solution and rescue patients from severe vision loss. Currently, the Institute is running several clinical trials\* in the patient recruitment phase for age-related macular degeneration (AMD), in both the dry (atrophic) and wet (exudative) forms of the disease.

* Clinical trials authorized by the AEMPS and the CEIm Grupo Hospitalario Quironsalud in Barcelona.

WHO CAN PARTICIPATE IN THESE CLINICAL TRIALS?

Patient access is determined through a thorough evaluation of the candidate’s profile and by confirming that specific eligibility criteria are met in order to take part in the study and receive the treatment. Based on all this information, the medical team makes the final approval decision.

WHAT ARE THE BENEFITS AND/OR RISKS OF PARTICIPATING IN A TRIAL? Participating in a clinical trial offers several advantages for the patient: it provides the opportunity to access the most innovative treatments, with personalized, cutting-edge care delivered by expert physicians. Moreover, for now, this is the only way to access new drugs that are not yet available to the general public. Clinical trials are conducted according to strict ethical and scientific standards. At the Institute, we follow national and international regulations and policies to protect the rights, safety, and well-being of all participants. The risks of participating in a clinical trial may arise from the route of drug administration on the one hand, and from the medication itself on the other. The risks related to administration are known and generally low; those related to the medication are only partially known, but are usually mild and limited to the eye. In any case, the patient will be informed by the investigator about the possible side effects and discomforts related to participation in the study, which may vary from one patient to another.
WHAT DOES IT COST FOR THE PATIENT? Selected patients do not have to pay for the treatment, so it is completely free of charge. HOW LONG DO CLINICAL TRIALS LAST? The duration depends on the specific trial and the results observed in the patient. In general, it usually lasts between one and two years at most.

If you want to participate in a clinical trial, send us your information and we will assess whether you are eligible:

The INSTITUT DE LA MÀCULA will process your data in order to respond to your inquiries, questions, or complaints. You may exercise your rights of access, rectification, erasure, portability, restriction, and objection, as explained in our Privacy Policy and Legal Notice.

Subscribe to our digital newsletter

We are committed to sending you only relevant information and never sharing your contact details.
Scroll to Top

SCHEDULE

WE CALL YOU

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.